Keyphrases
Multiple Myeloma
100%
Carfilzomib
100%
Exposure-response
100%
Population Pharmacokinetics
100%
Overall Response Rate
60%
Monotherapy
40%
Combination Therapy
40%
Adverse Events
20%
Clinically Significant
20%
Relapsed or Refractory
20%
Clinical Data
20%
Phase II Study
20%
Baseline Characteristics
20%
Intravenous Infusion
20%
Increasing Risk
20%
Consecutive Days
20%
Significant Relationship
20%
Body Surface Area
20%
Dose-ranging
20%
2-phase
20%
Treatment Refractory
20%
Exposure Risk
20%
Dosing Recommendations
20%
5-Phases
20%
Population Pharmacokinetic Analysis
20%
Maximum Permissible Concentration
20%
Population Pharmacokinetic Model
20%
Medicine and Dentistry
Multiple Myeloma
100%
Pharmacokinetics
100%
Carfilzomib
100%
Infusion
75%
Monotherapy
50%
Combination Therapy
50%
Adverse Event
25%
Intravenous Drug Administration
25%
Body Surface
25%
Nursing and Health Professions
Multiple Myeloma
100%
Carfilzomib
100%
Infusion
75%
Combination Therapy
50%
Monotherapy
50%
Intravenous Drug Administration
25%
Adverse Event
25%
Surface Area
25%
Efficacy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Carfilzomib
100%
Pharmacokinetics
100%
Combination Therapy
50%
Monotherapy
50%
Adverse Event
25%